AbbVie (ABBV) Earnings Date, Estimates & Call Transcripts $183.08 +1.94 (+1.07%) (As of 11/27/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AbbVie Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 7EstimatedActual EPS (Oct. 30) $3.00 Beat By $0.08 Consensus EPS (Oct. 30) $2.92 AbbVie announced Q3 2024 earnings on October 30, 2024, reporting an EPS of $3.00, which topped analysts' consensus estimates of $2.92 by $0.08. Quarterly revenue rose 3.8% year-over-year to $14.46 billion, above analyst estimates of $14.28 billion. With a trailing EPS of $2.88 and a P/E Ratio of 63.57, AbbVie's earnings are expected to grow 11.32% next year, from $10.95 to $12.19 per share. Conference Call TranscriptConference Call AudioSEC 10-Q/10-K FilingABBV Upcoming EarningsAbbVie's next earnings date is estimated for Friday, February 7, 2025, based off prior year's reporting schedules. Get AbbVie Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbbVie and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataABBV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ABBV Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. AbbVie Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20244$2.21$10.93$4.402.180 - 2.220Q2 20244$2.56$12.20$5.092.530 - 2.570Q3 20244$2.85$13.31$5.492.920 - 2.960Q4 20244$2.96$14.29$5.802.940 - 2.980FY 202416$10.58$50.73$20.77 Q1 20252$2.42$2.62$2.52 Q2 20252$3.02$3.37$3.20 Q3 20252$3.02$3.10$3.06 Q4 20252$3.25$3.27$3.26 FY 20258$11.71$12.36$12.04 Q1 20261$2.85$2.85$2.85 Q2 20261$3.29$3.29$3.29 Q3 20261$3.54$3.54$3.54 AbbVie Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/7/2025(Estimated)------- 10/30/2024Q3 2024$2.92$3.00+$0.08$5.12$14.28B$14.46B 7/25/2024Q2 2024$2.57$2.65+$0.08$4.53$14.02B$14.46B 5/3/2024Q1 2024$2.26$2.31+$0.05$3.85$11.93B$12.31B 2/2/2024Q4 2023$2.76$2.79+$0.03$5.12$14.02B$14.30B 10/27/2023Q3 2023$2.86$2.95+$0.09$4.90$13.72B$13.93B 7/27/2023Q2 2023$2.79$2.91+$0.12$4.68$13.52B$13.87B [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin4/27/2023Q1 2023$2.44$2.46+$0.02$4.79$12.23B$12.23B 2/9/2023Q4 2022$3.54$3.60+$0.06$5.82$15.30B$15.12B AbbVie Earnings - Frequently Asked Questions When is AbbVie's earnings date? AbbVie has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, February 7th, 2025 based off last year's report dates. Learn more on ABBV's earnings history. What guidance has AbbVie issued on next quarter's earnings? AbbVie updated its fourth quarter 2024 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of 2.940-2.980 for the period, compared to the consensus estimate of 2.950. The company issued revenue guidance of $14.8 billion-$14.8 billion, compared to the consensus revenue estimate of $14.6 billion. Did AbbVie beat their earnings estimates last quarter? In the previous quarter, AbbVie (NYSE:ABBV) reported $3.00 earnings per share (EPS) to beat the analysts' consensus estimate of $2.92 by $0.08. Learn more on analysts' earnings estimate vs. ABBV's actual earnings. How can I listen to AbbVie's earnings conference call? The conference call for AbbVie's latest earnings report can be listened to online. Listen to Conference Call How can I read AbbVie's conference call transcript? The conference call transcript for AbbVie's latest earnings report can be read online. Read Transcript How can I view AbbVie's earnings report? AbbVie's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does AbbVie generate each year? AbbVie (NYSE:ABBV) has a recorded annual revenue of $54.32 billion. How much profit does AbbVie generate each year? AbbVie (NYSE:ABBV) has a recorded net income of $4.86 billion. ABBV has generated $2.88 earnings per share over the last four quarters. What is AbbVie's price-to-earnings ratio? AbbVie (NYSE:ABBV) has a trailing price-to-earnings ratio of 63.57 and a forward price-to-earnings ratio of 16.72. The price/earnings-to-growth ratio is 2.02. What is AbbVie's EPS forecast for next year? AbbVie's earnings are expected to grow from $10.95 per share to $12.19 per share in the next year, which is a 11.32% increase. ` More Earnings Resources from MarketBeat Related Companies Eli Lilly and Company Earnings Results Johnson & Johnson Earnings Results Merck & Co., Inc. Earnings Results Pfizer Earnings Results Bristol-Myers Squibb Earnings Results Zoetis Earnings Results Royalty Pharma Earnings Results Jazz Pharmaceuticals Earnings Results Corcept Therapeutics Earnings Results Perrigo Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. This page (NYSE:ABBV) was last updated on 11/29/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABBV Stock Alerts